Amazon GLP-1 Treatment
Source: Amazon Inc.
Amazon is delving into the burgeoning weight loss market, unveiling a new program Tuesday that aims to simplify access to popular GLP-1 treatments.
The company said its primary care division, Amazon One Medical, is launching a GLP-1 management program that integrates obesity treatment into routine care. The offering combines virtual and in-person visits, prescription management and pharmacy compliance, positioning weight management as a long-term chronic condition rather than a one-time prescription.
“Providing customers with quick, convenient access to medications and clear, transparent pricing is integral to how Amazon Pharmacy is transforming the pharmacy experience,” Tanvi Patel, vice president and general manager of Amazon Pharmacy, said in the company's news release.
“By expanding access to the latest GLP-1 medications with clear, up-front pricing, we are making it easier for customers to get the treatments their healthcare providers prescribe and keep taking them because they are delivered reliably and directly to patients,” Patel said.
Through Amazon Pharmacy, patients will be able to access medications including Nordisk Wegovy, as well as newer GLP-1 oral options. Locked-in prices will start at $25 per month, Amazon said. For patients who pay cash, oral medications start at $149 per month, he said.
Injectable treatments, including Wegovy injections and Eli Lilly Zepbound starts at $299 per month when paid without insurance, Amazon said.
Those prices are roughly in line with much of the current market.
But Amazon's advantage is in same-day delivery and convenience as it looks to leverage its logistics network and reach another corner of the medical system.
The company also said it will offer on-demand prescription renewals, starting at $29 per message consultation and $49 per video consultation. Amazon plans to expand its same-day medication delivery offering to 4,500 cities by the end of 2026.
Shares of several companies linked to the rise of anti-obesity drugs fell after Amazon's Tuesday announcement, including Health for him and her, Viking therapeutics, amgen and Septerna.
